Case Study

MAbxience Optimizes And Accelerates Downstream Biosimilar Process Development

MAbxience Optimizes And Accelerates Downstream Biosimilar Process Development

Biosimilars represent an innovative solution that can benefit both patients and healthcare systems by reducing the burden of rising treatment costs. To improve the availability, price and access of medicines, many countries are implementing strategies to establish their own production capacity. To support this development, mAbxience, a Spanish biotechnology company specialized in research, development, and manufacture of biosimilar drugs, is committed to provide the manufacturing of high-quality products and processes that meet regulatory and technical requirements in all countries where it operates, using cutting edge single-use technology. Currently, mAbxience has sales contracts in more than 70 countries.

One of the biosimilar specialties present in mAbxience pipeline constitutes an Fc-fusion protein, with a molecular weight of Mr 150 000 and an isoelectric point of < 5, for which a first-generation process was established by a third-party contract manufacturing organization (CMO). The molecule exhibits monoclonal antibody (mAb) behavior, however, with a challenging glycosylation profile and complex tertiary and quaternary structures. Consequently, low product recovery and purity were obtained in the first-generation purification process. In addition, the purification protocols were poorly suited for manufacturing scale.

With the aim of improving the first-generation process to reach the manufacturability and purity required to produce material for phase I clinical trials, mAbxience contacted GE Healthcare’s Fast Trak Services team to initiate a collaborative project. This case study demonstrates the optimization of the downstream purification process to improve product purity and recovery of the biosimilar Fc-fusion protein. The optimization work was conducted by Fast Trak scientists. Process optimization focused  on improving the affinity chromatography (AF) capture step as well as the intermediate purification and polishing steps, using hydrophobic interaction chromatography (HIC) and anion exchange chromatography (AIEX), respectively, keeping the same process materials. In addition, a purification scheme more suitable for manufacturing scale was to be established.

Optimization of the capture step

The goal was to improve dynamic binding capacity (DBC) of the chromatography resin used in the capture step, while maintaining or improving yield. A comparison of several protein A affinity resins was conducted, from which the MabSelect SuRe™ resin was selected. MabSelect SuRe  resin was developed for process-scale mAb capture. The resin is designed with an alkali- and protease-stabilized, recombinant protein A ligand coupled to a rigid, high-flow agarose base matrix. The stability of the protein A ligand minimizes ligand leakage and allows for the use of rigorous and cost-effective cleaning procedures that include sodium hydroxide (NaOH). The highly cross-linked agarose base matrix of the resin enables the use of high flow velocities at manufacturing scale.

The DBC of the MabSelect SuRe resin was tested under the optimized conditions, and the results showed a  10% breakthrough at 24 mg mAb/L resin (Fig 1), a 100% improvement from the first-generation process.

Fig 1: Results from testing of DBC of MAbSelect SuRe resin

Optimization of the intermediate purification step

The aim of this step is to remove misfolded versions of the target molecule. However, the first-generation process offered poor resolution between correctly folded and misfolded target (Fig 2A).

The optimization goal for the intermediate purification step was to improve, not only manufacturability, but also product purity. Although a preliminary screening of alternative resins from GE found two candidate resins that offered significantly better resolution, implementing a new resin was not possible with the limited time before project delivery. Hence, the work focused on optimizing process conditions for the current resin.

Optimization of loading conditions and changing from gradient to step-wise elution resulted in improved resolution, generating increased product recovery from 30%–40% to about 50% and improved product purity (Fig 2B). However, the resin resolution was still too poor to remove impurities eluting at the front of the peak. Consequently, a partial gradient was still needed at the elution start to obtain the required product purity. Analysis of the purified protein by surface plasmon resonance (SPR) using a Biacore™ instrument verified a similar behavior of the target molecule to the originator molecule.

Fig 2. Chromatograms from intermediate purification step of (A - top) the original process and (B - bottom) the optimized process

Optimization of the polishing step

Q Sepharose™ Fast Flow anion exchange resin was used  in the polishing step. The resin was developed for industrial downstream processes and exhibits a high chemical stability, allowing for the use of well-proven cleaning-in-place (CIP) and sanitization protocols. The hydrophilic nature of the base matrix ensures low levels of non-specific binding, leading to low levels of host cell-derived impurities in the elution pool.

The aim of this step was to reduce charge variants to match the originator molecule. The first-generation process offered poor resolution, resulting in undesired basic charge variants in the product peak (Fig 3A). By optimizing loading conditions and changing from gradient to step-wise elution, resolution and product purity could be improved (Fig 3B). Also, the step yield could be increased from 60%–70% to about 90% using the optimized protocol. Analysis of the purified protein by SPR using a Biacore instrument verified a similar behavior of the target molecule to the originator molecule.

Fig 3. Chromatograms from the polishing step of (A - top) the original process and (B - bottom) the optimized process

Confirmation runs

The final optimized process conditions were confirmed in three consistency batches at 0.5 L scale. Manufacturing batch record and solution record documents were prepared by the Fast Trak Services team, and the results showed reproducibility in yield and purity between the runs. Based on these results, technology transfer documentation was prepared.

Process summary and discussion

Process improvements from the original process, using the optimized process, are listed in Figure 4. A final report was delivered in accordance with set timelines, and the documentation required for technology transfer was prepared by the Fast Trak Services team. To facilitate technology transfer, Fast Trak scientists worked directly with a third-party CMO. By defining process-critical parameters in a simulation of conditions of the scaled-up process, the optimized process was successfully scaled to 500 and 2000 L for cGMP clinical manufacturing.

Fig 4. Improvements from the original process, using the optimized process

Conclusion

Collaborative projects can help ease risk and cost  burdens, while increasing speed to market. This case study demonstrates the optimization of a downstream purification of a mAb biosimilar, as a collaboration between mAbxience and GE Healthcare’s Fast Trak Services team. Through resin selection and optimization of loading and elution conditions, product recovery, manufacturability, and purity could be greatly improved. DBC of the resin used in the initial capture step was doubled, and the recovery was significantly increased  over  the  subsequent  intermediate  purification and polishing steps.

We thank mAbxience, Spain, for kindly providing us with permission for use of this body of work as a demonstration of our Fast Trak Services.

"To speed up the process optimization of the described biosimilar product, collaboration with GE Healthcare’s Fast Trak Services team was crucial for mAbxience. Thanks to the strong expertise and commitment of the Fast Trak team to protein downstream processing, the work was carried out smoothly to achieve the expected results according to the agreed timeline. Due to the valuable outcomes of this synergy, mAbxience will continue to collaborate with GE Healthcare’s Fast Trak Services team on other biosimilar projects."

—Vincenzo Rivieccio (R&D Specialist, MAbxience, Spain)

About GE Fast Trak Services

GE’s Fast Trak Service Centers are specifically designed to help biopharmaceutical manufacturers increase their process productivity, reduce cost, and enable them to bring their product to market faster through a comprehensive range of services including cGMP manufacturing, process development, and training.

The centers are equipped with the latest single-use technologies for bioprocessing in an environment and at a scale that closely replicates the real-life industrial setting. For over 30 years, thousands of customers world-wide have been trained by GE’s experienced Fast Trak leadership teams, giving customers access to industry expertise encompassing process and analytical development, process scale-up, as well as manufacture of drug substances for use in toxicology studies or phase I and II clinical testing.

GE Healthcare has Fast Trak Centers in South Korea, the USA, Sweden, India, and China and satellite Fast Trak Centers in Turkey, Japan and Singapore.